Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp & Dohme, which acquired Mulford in 1929, and upon Merck & Co., Inc., which merged with Sharp & Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw extensively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.